Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast

被引:3
作者
Barbarroja, Nuria [1 ]
Lopez-Medina, Clementina [1 ]
Escudero-Contreras, Alejandro [1 ]
Arias-de la Rosa, Ivan [1 ]
机构
[1] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Dept Med & Surg Sci,Rheumatol Serv, Cordoba, Spain
关键词
apremilast; cardiometabolic comorbidities; cardiovascular disease; psoriatic arthritis; psoriasis; psoriatic disease; ORAL PHOSPHODIESTERASE-4 INHIBITOR; SEVERE PLAQUE PSORIASIS; CONTROLLED-TRIAL; RISK-FACTORS; INSULIN-RESISTANCE; PHASE-III; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME; CARDIOMETABOLIC PARAMETERS; RHEUMATOID-ARTHRITIS;
D O I
10.3389/fimmu.2024.1459185
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Psoriatic disease, encompassing both psoriasis (Pso) and psoriatic arthritis (PsA), is closely intertwined with a significantly elevated risk of developing cardiovascular diseases. This connection is further compounded by a higher prevalence of cardiometabolic comorbidities, including type 2 diabetes, obesity, insulin resistance, arterial hypertension, and dysregulated lipid profiles. These comorbidities exceed the rates seen in the general population and compound the potential for increased mortality among those living with this condition. Recognizing the heightened cardiometabolic risk inherent in psoriatic disease necessitates a fundamental shift in the treatment paradigm. It is no longer sufficient to focus solely on mitigating inflammation. Instead, there is an urgent need to address and effectively manage the metabolic parameters that have a substantial impact on cardiovascular health. Within this context, apremilast emerges as a pivotal treatment option for psoriatic disease. What sets apremilast apart is its dual-action potential, addressing not only inflammation but also the critical metabolic parameters. This comprehensive treatment approach opens up new opportunities to improve the well-being of people living with psoriatic disease. This review delves into the multifaceted aspects involved in the development of cardiovascular disease and its intricate association with psoriatic disease. We then provide an in-depth exploration of the pleiotropic effects of apremilast, highlighting its potential to simultaneously mitigate metabolic complications and inflammation in individuals affected by these conditions.
引用
收藏
页数:12
相关论文
共 89 条
[1]   The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast [J].
Arias de la Rosa, Ivan ;
Dolores Lopez-Montilla, Maria ;
Roman-Rodriguez, Cristobal ;
Perez-Sanchez, Carlos ;
Gomez-Garcia, Ignacio ;
Lopez-Medina, Clementina ;
Lourdes Ladehesa-Pineda, Maria ;
Del Carmen Abalos-Aguilera, Maria ;
Ruiz, Desiree ;
Maria Patino-Trives, Alejandra ;
Luque-Tevar, Maria ;
Anon-Onate, Isabel ;
Jose Perez-Galan, Maria ;
Guzman-arbarroja, Rocio ;
Malagon, Maria M. ;
Lopez-Pedrera, Chary ;
Escudero-Contreras, Alejandro ;
Collantes-Estevez, Eduardo ;
Barbarroja, Nuria .
JOURNAL OF INTERNAL MEDICINE, 2022, 291 (05) :676-693
[2]   Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis [J].
Arias de la Rosa, Ivan ;
Font, Pilar ;
Escudero-Contreras, Alejandro ;
Dolores Lopez-Montilla, Maria ;
Perez-Sanchez, Carlos ;
Carmen Abalos-Aguilera, Maria ;
Ladehesa-Pineda, Lourdes ;
Ibanez-Costa, Alejandro ;
Torres-Granados, Carmen ;
Jimenez-Gomez, Yolanda ;
Patino-Trives, Alejandra ;
Luque-Tevar, Maria ;
Carmen Castro-Villegas, Maria ;
Calvo-Gutierrez, Jerusalem ;
Ortega-Castro, Rafaela ;
Lopez-Pedrera, Chary ;
Collantes-Estevez, Eduardo ;
Barbarroja, Nuria .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
[3]   Psoriasis and the Risk of Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Armstrong, April W. ;
Harskamp, Caitlin T. ;
Armstrong, Ehrin J. .
JAMA DERMATOLOGY, 2013, 149 (01) :84-91
[4]   Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk [J].
Barbarroja, Nuria ;
Ruiz-Ponce, Miriam ;
Cuesta-Lopez, Laura ;
Perez-Sanchez, Carlos ;
Lopez-Pedrera, Chary ;
Arias-de La Rosa, Ivan ;
Collantes-Estevez, Eduardo .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[5]   Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis [J].
Barbarroja, Nuria ;
Arias-de la Rosa, Ivan ;
Lopez-Medina, Clementina ;
del Rosario Camacho-Sanchez, Maria ;
Gomez-Garcia, Ignacio ;
Jose Velez-Garcia, Antonio ;
Escudero-Contreras, Alejandro ;
Lopez-Pedrera, Chary ;
Dolores Lopez-Montilla, Maria ;
Collantes-Estevez, Eduardo .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2019, 11
[6]   The obese healthy paradox: is inflammation the answer? [J].
Barbarroja, Nuria ;
Lopez-Pedrera, Rosario ;
Dolores Mayas, Maria ;
Garcia-Fuentes, Eduardo ;
Garrido-Sánchez, Lourdes ;
Macias-Gonzalez, M. ;
El Bekay, Rajaa ;
Vidal-Puig, Antonio ;
Tinahones, Francisco J. .
BIOCHEMICAL JOURNAL, 2010, 430 :141-149
[7]   Psoriasis [J].
Boehncke, Wolf-Henning ;
Schoen, Michael P. .
LANCET, 2015, 386 (9997) :983-994
[8]   Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia [J].
Bonetti, PO ;
Pumper, GM ;
Higano, ST ;
Holmes, DR ;
Kuvin, JT ;
Lerman, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2137-2141
[9]   Insulin Resistance, Hyperglycemia, and Atherosclerosis [J].
Bornfeldt, Karin E. ;
Tabas, Ira .
CELL METABOLISM, 2011, 14 (05) :575-585
[10]   Cardiovascular disease in inflammatory rheumatic diseases [J].
Castaneda, Santos ;
Nurmohamed, Michael T. ;
Gonzalez-Gay, Miguel A. .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2016, 30 (05) :851-869